ValuEngine Downgrades Ra Pharmaceuticals (NASDAQ:RARX) to Hold

Ra Pharmaceuticals (NASDAQ:RARX) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Wednesday, ValuEngine reports.

Several other equities analysts also recently weighed in on RARX. Robert W. Baird initiated coverage on shares of Ra Pharmaceuticals in a report on Thursday, June 20th. They set an “outperform” rating for the company. Zacks Investment Research upgraded shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BMO Capital Markets set a $42.00 price target on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group lifted their price target on shares of Ra Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, June 18th. Finally, BidaskClub downgraded shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 13th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $38.63.

NASDAQ:RARX traded up $0.54 during mid-day trading on Wednesday, hitting $24.17. 545,018 shares of the company’s stock traded hands, compared to its average volume of 473,693. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.30 and a current ratio of 15.30. The firm’s 50 day simple moving average is $26.33 and its 200 day simple moving average is $26.15. Ra Pharmaceuticals has a 1 year low of $11.27 and a 1 year high of $36.96. The company has a market cap of $1.11 billion, a PE ratio of -11.73 and a beta of 1.34.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.03). On average, research analysts expect that Ra Pharmaceuticals will post -1.97 earnings per share for the current fiscal year.

In related news, insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $33.10, for a total value of $350,694.50. Following the sale, the insider now directly owns 8,521 shares of the company’s stock, valued at $282,045.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Simon Read sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $25.41, for a total transaction of $254,100.00. Following the completion of the sale, the insider now directly owns 16,234 shares in the company, valued at $412,505.94. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,190 shares of company stock valued at $1,479,624. Insiders own 4.30% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its position in shares of Ra Pharmaceuticals by 218.0% in the second quarter. Bank of Montreal Can now owns 3,832 shares of the company’s stock worth $115,000 after acquiring an additional 2,627 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Ra Pharmaceuticals in the first quarter worth approximately $229,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Ra Pharmaceuticals in the first quarter worth approximately $304,000. Virginia Retirement Systems ET AL boosted its position in shares of Ra Pharmaceuticals by 12.9% in the second quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after acquiring an additional 1,200 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Ra Pharmaceuticals in the second quarter worth approximately $373,000. 91.59% of the stock is currently owned by institutional investors and hedge funds.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Sell-Side Analysts

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.